Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:27 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting First Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

NCT00833521
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

NCT01768559
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Nov 1, 2026, 1:27 AM EST
Recruiting Not applicable Interventional

EMPOWER: Effects of Weight Loss and Exercise Post-stroke

NCT05901675
View directory record Official record
Conditions
Obesity, Stroke
Interventions
Lifestyle Management Program, Post-stroke Optimization of Walking using Explosive Resistance
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
35 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers

NCT01037725
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo to AZD5847
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Nov 1, 2026, 1:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Fasting ENHANCE Pilot Study

NCT05732935
View directory record Official record
Conditions
Overweight and Obesity, Time Restricted Feeding, Alzheimer Disease
Interventions
Time Restricted Eating intervention, Successful Aging Comparison Group (LEARN)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Recruiting No phase listed Observational

Respiration From Pleth Validation

NCT07449715
View directory record Official record
Conditions
Respiratory Rate Monitoring
Interventions
Physiological Monitoring with SpO₂ Sensors and Capnography
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
4 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of an Antioxidant Supplement on Blood Vessel Health

NCT06424756
View directory record Official record
Conditions
Healthy
Interventions
MitoQ, Placebo, MitoTempo, Tempol, L-NAME, SNP - Sodium Nitroprusside
Dietary Supplement · Drug
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Early Phase 1 Interventional

Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)

NCT06961851
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
aTMS utilizing the MagVenture TMS device
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

NCT04096157
View directory record Official record
Conditions
Healthy Subjects
Interventions
Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)

NCT06719557
View directory record Official record
Conditions
Healthy
Interventions
Calderasib, Itraconazole, Phenytoin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

NCT02948569
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
3-V Bioscience-2640
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
35 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Nov 1, 2026, 1:27 AM EST
Active, not recruiting Phase 1 Interventional

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

NCT05944562
View directory record Official record
Conditions
Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome
Interventions
Tulmimetostat
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Energy Expenditure and Substrate Utilization During Acute Under- and Over-feeding

NCT01740765
View directory record Official record
Conditions
Obesity
Interventions
24-hour energy expenditure
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

NCT00302393
View directory record Official record
Conditions
Healthy
Interventions
OROS methylphenidate hydrochloride, methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zaleplon 10mg Capsules Under Fasting Conditions

NCT00829998
View directory record Official record
Conditions
Healthy
Interventions
Zaleplon 10 mg Capsules, Sonata® 10 mg Capsules
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 2 Interventional Results available

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

NCT02414139
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
13
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

NCT03518554
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
Interventions
JAB-3068
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Itraconazole Oral Absorption

NCT04035187
View directory record Official record
Conditions
Fungal Infection
Interventions
fast itraconazole tablet, medium itraconazole tablet, slow itraconazole tablet, oral itraconazole solution
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Nov 1, 2026, 1:27 AM EST
Completed Not applicable Interventional Results available

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life

NCT03757988
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
Exercise Intervention- PACE-Life
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Nov 1, 2026, 1:27 AM EST
Recruiting Phase 1 Interventional

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172
View directory record Official record
Conditions
Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
Drug · Combination Product · Other
Lead sponsor
Epkin
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Beverly Hills, California • Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

NCT00829309
View directory record Official record
Conditions
Healthy
Interventions
Pravastatin
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Nov 1, 2026, 1:27 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

NCT03061981
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Metformin, DA-1241
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Nov 1, 2026, 1:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Fuzzy AI Using VR for Collision Prevention

NCT03915119
View directory record Official record
Conditions
Injuries
Interventions
GFT AI training
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 22 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 1, 2026, 1:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer

NCT04763902
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Time Restricted Eating (TRE) Schedule, Control Schedule
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 1, 2026, 1:27 AM EST